Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
August 01 2022 - 7:00AM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
panel discussions at the BTIG Biotechnology Conference on August
8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on
August 10th.
A webcast of the panels will be available in the “Events &
Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcast will be available on the website for 90
days.
Conference Details: |
Event: |
BTIG Biotechnology Conference |
Topic: |
AAV Gene Therapies for CNS Disorders: Challenges and
Opportunities |
Date: |
Monday August 8 |
Time: |
12:00 pm ET |
Format: |
Panel discussion |
Participant: |
Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical
Officer and Head of Research and Development |
|
|
Event: |
2022 Wedbush PacGrow Healthcare Virtual Conference |
Topic: |
UltraOrphan: When You’re One in a Million |
Date: |
Wednesday, August 10 |
Time: |
9:45 am ET |
Format: |
Panel discussion |
Participant: |
RA Session II, President, Founder and Chief Executive Officer |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
Company Contact:Kimberly Lee, D.O. Chief
Corporate Affairs OfficerTaysha Gene
Therapiesklee@tayshagtx.com
Media Contact:Carolyn HawleyEvoke
Canalecarolyn.hawley@evokegroup.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024